Investigating a new treatment approach for Alzheimer's disease and related dementias
Official title: Targeting P2RX7 Signaling as a Treatment for ADRD
Funded at Indiana University Indianapolis · NIH-11170831 · Data updated 2026-11-12
This study is looking at how a specific receptor in the brain, called P2RX7, might help improve treatments for Alzheimer's disease and related dementias by understanding its role in brain inflammation and cell health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | September 30, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $792,498 |
| NIH project number | 1R56AG085396-01A1 |
| Project ID | NIH-11170831 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with Alzheimer's disease or related dementias.
✕Less likely to help
Patients who do not have Alzheimer's disease or related dementias may not benefit from this research.
What this research studies
This research focuses on understanding how targeting a specific receptor, P2RX7, can help treat Alzheimer's disease and related dementias (ADRD). The study examines the role of neuroinflammation in these conditions and how purinergic receptors, particularly P2X7, contribute to cellular dysfunction. By exploring the mechanisms of these receptors and their activation by extracellular ATP, the research aims to identify potential therapeutic strategies that could improve patient outcomes. The approach involves both laboratory studies and potential future clinical applications.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that alleviate symptoms or slow the progression of Alzheimer's disease and related dementias.
How similar studies have gone: Previous research has shown promise in targeting purinergic receptors for neurodegenerative diseases, suggesting that this approach may yield beneficial results.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Territo, Paul Richard — Indiana University Indianapolis
- Study coordinator: Territo, Paul Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.